Antibiotic resistance is a looming public health crisis. New antibiotics with new mechanisms of action are desperately needed. The long-term goal of this research is to develop new drugs that disarm bacteria to overcome the problem of antibiotic resistance.
Signaling Pathways To Enhance Potency Of AMPK-targeting Drugs
Funder
National Health and Medical Research Council
Funding Amount
$661,966.00
Summary
Sedentary lifestyles and consumption of high energy foods has led to epidemics of obesity-related metabolic diseases that place enormous financial and medical burden on the Australian economy. An attractive drug target to treat these diseases is AMP-activated protein kinase (AMPK) which functions as both a cellular fuel gauge and co-ordinator of whole-body metabolism. Our goal is to improve AMPK drug potency by identifying novel processes that sensitize AMPK to drugs.
Identifying Novel Long-noncoding RNAs Involved In The Development Of Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$785,204.00
Summary
Recent studies have identified regions within the human genome in which DNA sequence variations are associated with an increased risk of breast cancer. The aim of this proposal is to identify and characterise these non-coding genes that are modulate breast cancer risk. Understanding how sequences variations that alter these novel genes contribute to breast cancer will provide novel avenues for therapy.
Structural And Functional Analysis Of A Cancer-linked Co-regulator Complex
Funder
National Health and Medical Research Council
Funding Amount
$729,571.00
Summary
We seek to understand the mechanisms by which genes are switched on and off throughout our lifetime. A number of multi-component protein machines are involved in this process but their make-up and mechanism of action is not understood. We will investigate the structure and function of one of these machines that has been strongly linked to cancer.
Functional Analysis Of Breast Cancer Susceptibility Regions
Funder
National Health and Medical Research Council
Funding Amount
$790,588.00
Summary
Recent studies have identified regions within the human genome in which DNA sequence variations are associated with an increased risk of breast cancer. Several of these regions do not contain any known genes, suggesting that regulatory DNA sequences are responsible for the associated risk. The aim of this proposal is to identify and characterise these DNA sequences. Understanding how sequences variations in these regions contribute to breast cancer will provide novel avenues for therapy.
A Structural Understanding Of Class B G Protein-coupled Receptor Function
Funder
National Health and Medical Research Council
Funding Amount
$1,289,570.00
Summary
G protein-coupled receptors (GPCRs) are the largest family of cell surface proteins that enable communication from external signals to the inside of cells of the body. Class B GPCRs are a therapeutically important subclass of these receptors and they play crucial roles in bone and energy homeostasis, cardiovascular control and immune response. This grant will uncover fundamental knowledge on how these receptors work, and will enhance future development of therapeutics.
Novel Interventions To Address Methamphetamines In Aboriginal Communities, Including A Randomised Trial Of A Web Based Therapeutic Tool Used To Treat Dependence In Clinical Settings.
Funder
National Health and Medical Research Council
Funding Amount
$2,177,908.00
Summary
Methamphetamine use in Aboriginal communities has gained much media attention, despite limited research studies to ascertain the full extent of its use and its impact. We propose a randomised trial of a web based therapeutic tool for use in Aboriginal Medical Services to treat clients using methamphetamines. In addition we will characterise the health and well-being of Aboriginal people who use methamphetamines and trial unique Aboriginal community led interventions to address methamphetamines.
Immuno-polymeric Drugs For Prostate Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$626,995.00
Summary
Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.
Targeted Development Of AMPK Β2-isoform Allosteric Activators
Funder
National Health and Medical Research Council
Funding Amount
$898,147.00
Summary
Sedentary lifestyles and consumption of high energy foods has led to dramatic increases in the incidence of diseases associated with metabolic dysregulation e.g. type 2 diabetes. An attractive drug target to treat these diseases is AMP-activated protein kinase (AMPK) which functions as a cellular fuel gauge. We have discovered a new drug that crucially activates the form of AMPK found in metabolically active organs. We aim to develop this drug to unlock new therapeutic opportunity.
Identification Of Germline Variation That Predicts Progression Free Survival Following Chemotherapy For Advanced Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$633,156.00
Summary
Women diagnosed with ovarian cancer typically undergo surgery, followed by chemotherapy. However, the efficacy of chemotherapy varies widely, with some women responding well, whilst others are exposed to the toxic effects of a treatment that does them little good. We aim to identify the genes which explain why there are differences in response. This will lead to more individualised chemotherapy and improved outcomes for women with ovarian cancer.